文献速递类风湿关节炎

类风湿关节炎的早期识别:是否能带来治疗相关费用的节省?

Early identification of rheumatoid arthritis: does it induce treatment-related cost savings?
PubMed 文献 · Ann Rheum Dis · 2024-11-14

研究纳入2011至2017年Leiden早期关节炎门诊连续入组的431例类风湿关节炎患者,以症状持续时间<12周定义早期治疗启动,比较早期与晚期诊断分组5年内改善病情抗风湿药相关费用。自身抗体阴性组晚期费用较早期高316%(4856欧元 vs 1159欧元),自身抗体阳性组高19%(9418欧元 vs 7934欧元)。

要点

  • 自身抗体阴性类风湿关节炎晚期诊断组5年治疗相关费用较早期组高316%(4856欧元 vs 1159欧元)。
  • 自身抗体阳性类风湿关节炎晚期组费用较早期组高19%(9418欧元 vs 7934欧元),效应较小。
  • 使用生物制剂的自身抗体阳性患者中,晚期治疗启动与费用高46%相关(β=1.46,95%CI 0.91至2.33)。

核心结论

  • 在症状出现后12周内发现类风湿关节炎时,自身抗体阴性和自身抗体阳性患者的治疗相关费用均较低。
  • 本研究首次报告早期诊断和治疗启动对治疗相关费用的影响。

研究设计与样本

  • 研究纳入2011至2017年间连续进入Leiden早期关节炎门诊的类风湿关节炎患者,共431例。
  • 症状持续时间定义为症状出现至首次就诊于门诊的时间,早期治疗启动定义为症状持续时间<12周。
  • 从患者病历处方数据获取每例患者5年内改善病情抗风湿药使用信息,分别采用2022年和2012年价格分析药物费用变化的影响。
  • 因疾病严重程度差异可能影响费用,自身抗体阳性和自身抗体阴性类风湿关节炎分别分析。

主要发现

  • 自身抗体阴性类风湿关节炎中,晚期组费用较早期组高316%(β=4.16,95%CI 1.57至11.1;4856欧元 vs 1159欧元),采用2012年价格结果相似。
  • 自身抗体阳性类风湿关节炎中,晚期组费用较早期组高19%(9418欧元 vs 7934欧元,β=1.19,95%CI 0.57至2.47),采用2012年价格时该效应存在但较小。
  • 使用生物制剂的自身抗体阳性类风湿关节炎患者中,晚期治疗启动与费用高46%相关(β=1.46,95%CI 0.91至2.33),采用2012年价格时也观察到更高费用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Early diagnosis and treatment-start is key for rheumatoid arthritis (RA), but the economic effect of an early versus a later diagnosis has never been investigated. We aimed to investigate whether early diagnosis of RA is associated with lower treatment-related costs compared with later diagnosis. METHODS: Patients with RA consecutively included in the Leiden Early Arthritis Clinic between 2011 and 2017 were studied (n=431). Symptom duration was defined as the time between symptom onset and first presentation at the outpatient clinic; early treatment start was defined as symptom duration <12 weeks. Information on disease-modifying anti-rheumatic drug use per patient over 5 years was obtained from prescription data from patient records. Prices were used from 2022 and 2012 (proxy of time of prescription) to study the impact of changes in drug costs. Autoantibody-positive and autoantibody-negative RA were studied separately because differences in disease severity may influence costs. RESULTS: Within autoantibody-negative RA, costs were 316% higher in the late compared with the early group (β=4.16 (95% CI 1.57 to 11.1); €4856 vs €1159). When using 2012 prices, results were similar. For autoantibody-positive RA, costs were 19% higher in the late group (€9418 vs €7934, β=1.19, 0.57 to 2.47). This effect was present but smaller when using 2012 prices. Within patients with autoantibody-positive RA using biologicals, late treatment start was associated with 46% higher costs (β=1.46 (0.91 to 2.33)); higher costs were also seen when using 2012 prices. CONCLUSION: When RA is detected within 12 weeks after symptom onset, treatment-related costs were lower in both autoantibody-negative and autoantibody-positive RA. This study is the first to report how early diagnosis and treatment start impact treatment-related costs.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Mulligen E, Rutten-van Mölken M, van der Helm-van Mil A, et al. Early identification of rheumatoid arthritis: does it induce treatment-related cost savings? Ann Rheum Dis. 2024. PMID: 39019569. doi:10.1136/ard-2024-225746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。